iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Core Insights - iTeos Therapeutics, Inc. announced the presentation of preclinical data on EOS-215, an antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the AACR Annual Meeting in April 2025 [1][2] Company Overview - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics, leveraging expertise in tumor immunology and immunosuppressive pathways [3] - The company is headquartered in Watertown, MA, with a research center in Gosselies, Belgium [3] Product Details - EOS-215 is a potential best-in-class monoclonal antibody that reprograms tumor-associated macrophages to enhance T cell activation, showing efficacy in immune-resistant models [4] - The novel small molecule targeting PTPN1/2 enhances antitumoral responses by reshaping the tumor microenvironment and sensitizing cancer and immune cells to IFNγ [5] Presentation Information - iTeos will present two abstracts at the AACR Annual Meeting: one on EOS-215 and another on the PTPN1/2 inhibitor, with specific session details provided [6]